The company has secured contracts worth $1.7M for a recently acquired AI-powered advertising business in its portfolio.

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biopharmaceutical company with a market capitalization of $83.66 million and currently trading at $0.66 per share, held a Special Meeting of Stockholders ...

Global biopharmaceutical manufacturing firm Rentschler Biopharma will shutter its United Kingdom facility as the ...

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of ...

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

"We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...